Description
The US is a global leader in introducing new medical products, but the ability to generate evidence to inform clinical practice in postmarket settings must improve. Insurers may have an important role to play. Robert M. Califf, MD, of the US Food and Drug Administration, discusses why and how payers could support evidence generation with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS.
Related Content:
Why Evidence Generation Should Matter to Payers and How They Can Help
Pericarditis accounts for up to 5% of emergency department visits for nonischemic chest pain in North America and Western Europe. JAMA Review author Paul C. Cremer, MD, MS, discusses the recommended treatments for acute pericarditis and more with JAMA Associate Editor David L. Simel, MD, MHS.
...
Published 09/05/24
JAMA Editor in Chief Kirsten Bibbins-Domingo reviews 4 JAMA trials presented at this year’s European Society of Cardiology (ESC) Congress on antihypertensive continuation before elective surgery, potassium supplementation after cardiac surgery, pulmonary vein isolation for symptomatic atrial...
Published 09/02/24